21
別紙４ 研究成果の刊行に関する一覧表
雑誌
発表者氏名 論文タイトル名 発表誌名 巻号 ページ 出版年
Kai H, Akamatsu E, Torii E, Kodama H, Yukizaki C, Akagi I, Ino H, Sakakibara Y, Suiko M, Yamamoto I, Okayama A, Mor- ishita K, Kataoka H, Matsuno K.
Identification of a bioac- tive compound against adult T-cell leukemia from bitter gourd seeds.
Plants 3 18-26 2014
Nakahata S, Ichikawa T, Maneesaay P, Saito Y, Nagai K, Tamura T, Manachai N, Yama- kawa N, Hamasaki M,
Kitabayashi I, Arai Y, Kanai Y, Taki T, Abe T, Kiyonari H, Shimoda K, Ohshima K, Horii A, Shima H, Taniwaki M, Yama- guchi R, Morishita K.
Loss of NDRG2 expres- sion activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers.
Nature Comm. 5 3393 2014
Saito Y, Kaneda K, Suekane A, Ichihara E, Nakahata S, Yama- kawa N, Nagai K, Mizuno N, Kogawa K, Miura I, Itoh H, Morishita K.
Maintenance of the hem- atopoietic stem cell pool in bone marrow niches by EVI1-regulated GPR56.
Leukemia 27 1637-1649 2013
Yamasaki M, Mine Y, Nishimura M, Fujita S, Sakakibara Y, Suiko M, Morishita K, Nishiyama K.
Genistein induces apop- totic cell death associated with inhibition of the NF-κB pathway in adult T-cell leukemia cells.
Cell Biol Int. 37 742-747 2013
Sugie S, Mukai S, Tsukino H, Toda Y, Yamauchi T, Nishikata I, Kuroda Y, Morishita K, Ka- moto T.
Increased plasma caveo- lin-1 levels are associated with progression of pros- tate cancer among Japa- nese men.
Anticancer Res. 33 1893-1897 2013
Ikebe E, Kawaguchi A, Tezuka K, Taguchi S, Hirose S, Matsu- moto T, Mitsui T, Senba K, Nishizono A, Hori M, Hasegawa H, Yamada Y, Ueno T, Tanaka Y, Sawa H, Hall W, Minami Y, Jeang KT, Ogata M, Morishita K, Hasegawa H, Fujisawa J, Iha H.
Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and im- proves survival period for ATL model mice.
Blood Cancer J. 3 e132 2013
Yamamura A, Miura K, Ka- rasawa H, Morishita K, Abe K, Mizuguchi Y, Saiki Y, Fukushi- ge S, Kaneko N, Sase T, Nagase H, Sunamura M, Motoi F, Egawa S, Shibata C, Unno M, Sasaki I, Horii A.
Suppressed expression of NDRG2 correlates with poor prognosis in pancre- atic cancer.
Biochem Bio- phys Res Com- mun.
441 102-107 2013
22 Kondo Y, Nagai K, Nakahata S,
Saito Y, Ichikawa T, Suekane A, Taki T, Iwakawa R, Enari M, Taniwaki M, Yokota J, Sakoda S, Morishita K.
Overexpression of the DNA sensor proteins, absent in melanoma 2 and interferon-inducible 16, contributes to tumorigen- esis of oral squamous cell carcinoma with p53 inac- tivation.
Cancer Sci. 103 782-790 2012
Nakahata S, Saito Y, Marutsuka K, Hidaka T, Maeda K,
Hatakeyama K, Shiraga T, Goto A, Takamatsu N, Asada Y, Utsunomiya A, Okayama A, Kubuki Y, Shimoda K, Ukai Y, Kurosawa G, Morishita K.
Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma.
Leukemia 26 1238-1246 2012
Nakahata S, Morishita K. CADM1/TSLC1 is a nov- el cell surface marker for adult T-cell leuke- mia/lymphoma.
J Clin Exp
Hematopathol. 52 17-22 2012
Ueno S, Umeki K, Takajo I, Na- gatomo Y, Kusumoto N, Umekita K, Morishita K, Oka- yama A.
Proviral loads of human T-lymphotropic virus Type 1 in asymptomatic carriers with different infection routes
Int J Cancer. 130 2318-2326 2012
Takenouchi H, Umeki K, Sasaki D, Yamamoto I, Nomura H, Takajo I, Ueno S, Umekita K, Kamihira S, Morishita K, Oka- yama A.
Defective human
T-lymphotropic virus type 1 provirus in asympto- matic carriers.
Int J Cancer 128 1335-1343 2011
Saito Y, Nakahata S, Yamakawa N, Kaneda K, Ichihara E, Suekane A, Morishita K.
CD52 as a molecular tar- get for immunotherapy to treat acute myeloid leu- kemia with high EVI1 expression.
Leukemia 25 921-931 2011
Nishikata I, Nakahata S, Saito Y, Kaneda K, Ichihara E, Yamaka- wa N, Morishita K.
Sumoylation of MEL1S at lysine 568 and its interac- tion with CtBP facilitates its repressor activity and the blockade of
G-CSF-induced myeloid differentiation.
Oncogene 30 4194-4207 2011
23 Ichihara E, Kaneda K, Saito Y,
Yamakawa N, Morishita K. Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1 high leukemia cells.
Biochem Bio- phys Res Com- mun
416 239–245 2011
Yamakawa N, Kaneda K, Saito
Y, Ichihara E, Morishita K. The increased expression of integrin α6 (ITGA6) Enhances drug resistance in EVI1high leukemia.
PLoS One 7 e30706 2012
Tanaka-Nakanishi A, Yasunaga J, Takai K, Matsuoka M.
HTLV-1 bZIP Factor Su ppresses Apoptosis by Attenuating the Function of FoxO3a and Alterin g Its Localization.
Cancer Res 74 188-200 2014
Miura M, Yasunaga J, Tanabe J, Sugata K, Zhao T, Ma G, Miyazato P, Ohshima K, Kan eko A, Watanabe A, Saito A, Akari H, Matsuoka M.
Characterization of simia n T-cell leukemia virus type 1 in naturally infec ted Japanese macaques as a model of HTLV-1 infection.
Retrovirology 10 118 2013
Matsuoka M and Yasunaga J. Human T-cell leukemia virus type 1: replication, proliferation and propa gation by Tax and HTL V-1 bZIP factor.
Curr Opin Virol 3 684-691 2013
Zane L, Yasunaga J, Mitagami Y, Yedavalli V, Tang SW, C hen CY, Ratner L, Lu X, Jean g KT.
Wip1 and p53 contribut e to HTLV-1 Tax-induc ed tumorigenesis.
Retrovirology 9 114 2012
Ma G, Yasunaga J, Fan J, Ya nagawa S, Matsuoka M.
HTLV-1 bZIP factor dy sregulates the Wnt path ways to support prolifer ation and migration of a dult T-cell leukemia cell s.
Oncogene 32 4222-4230 2013
24 Sugata K, Satou Y, Yasunaga
JI, Hara H, Ohshima K, Utsun omiya A, Mitsuyama M, Mats uoka M.
HTLV-1 bZIP factor im pairs cell-mediated imm unity by suppressing pro duction of Th1 cytokine s.
Blood 119 434-444 2012
Yasunaga J and Matsuoka M. Molecular mechanisms o f HTLV-1 infection and pathogenesis.
Int. J. Hematol 94 435-442 2011
Yasunaga J, Lin FC, Lu X, Je
ang KT. Ubiquitin-specific peptid
ase 20 (USP20) targets TRAF6 and HTLV-1 Ta x to negatively regulate NF-κB signaling.
J Virol 85 6212-6219 2011
Hagiya K, Yasunaga JI, Satou
Y, Oshima K, Matsuoka M. ATF3, an HTLV-1 bZip factor binding protein, promotes proliferation of adult T-cell leukemia c ells.
Retrovirology 8 19 2011
